Rapid generation of Col7a1−/− mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells
View/ Open
Author
Webber, Beau R.
O’Connor, Kyle T.
McElmurry, Ron T.
Durgin, Elise N.
Eide, Cindy
Lees, Christopher J.
Riddle, Megan J.
Mathews, Wendy
Kluth, Mark A.
Ganss, Christoph
Moriarity, Branden S.
Osborn, Mark J.
Tolar, Jakub
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/labinvest.2017.85Metadata
Show full item recordCitation
Webber, B. R., K. T. O’Connor, R. T. McElmurry, E. N. Durgin, C. Eide, C. J. Lees, M. J. Riddle, et al. 2017. “Rapid generation of Col7a1−/− mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells.” Laboratory investigation; a journal of technical methods and pathology 97 (10): 1218-1224. doi:10.1038/labinvest.2017.85. http://dx.doi.org/10.1038/labinvest.2017.85.Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a debilitating and ultimately lethal blistering disease caused by mutations to the Col7a1−/− gene. Development of novel cell therapies for the treatment of RDEB would be fostered by having immunodeficient mouse models able to accept human cell grafts; however, immunodeficient models of many genodermatoses such as RDEB are lacking. To overcome this limitation, we combined the clustered regularly interspaced short palindromic repeats and associated nuclease (CRISPR/Cas9) system with microinjection into NOD/SCID IL2rγcnull (NSG) embryos to rapidly develop an immunodeficient Col7a1−/− mouse model of RDEB. Through dose optimization, we achieve F0 biallelic knockout efficiencies exceeding 80%, allowing us to quickly generate large numbers of RDEB NSG mice for experimental use. Using this strategy, we clearly demonstrate important strain-specific differences in RDEB pathology that could underlie discordant results observed between independent studies and establish the utility of this system in proof-of-concept human cellular transplantation experiments. Importantly, we uncover the ability of a recently identified skin resident immunomodulatory dermal mesenchymal stem cell marked by ABCB5 to reduce RDEB pathology and dramatically extend the lifespan of RDEB NSG mice via reduced skin infiltration of inflammatory myeloid derivatives.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623156/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981946
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)